April 8, 2019 | By John Raslavsky | Publications
This article provides expert guidance on the management of pruritus symptoms in patients receiving obeticholic acid (OCA) as treatment for primary biliary cholangitis (PBC).
April 8, 2019 | By John Raslavsky | Publications
In this review we critically assess the literature to evaluate the level of risk posed by alcohol as both a primary etiology of hepatocellular carcinoma (HCC) and
April 8, 2019 | By John Raslavsky | Publications
Abstract: Hepatitis C virus (HCV) infects more than 185 million individuals worldwide. Twenty percent of patients chronically infected with HCV progress to cirrhosis. New, simpler therapeutics using direct-acting antivirals that target various stages of the HCV life cycle are in development to eradicate HCV without concomitant interferon.
April 8, 2019 | By John Raslavsky | Publications
The interferon (IFN)–free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. However, sofosbuvir plus ribavirin therapy is associated with relapse in 15% to 30% of patients with HCV GT-1.
March 22, 2019 | By John Raslavsky | Publications
If you’re a liver patient, your diet is adjusted to meet your individual needs. Talk to your doctor about what’s best for you. Still, here are some general food tips for a healthy or healthier liver:
March 22, 2019 | By John Raslavsky | Publications
Abstract: Hepatitis C virus (HCV) infection is the leading reason for liver transplantation and a common cause of hepatocellular carcinoma, the most rapidly increasing cause of cancer-related deaths…